NewsEvents

Your Yourlocation: Home > Efficacy of tiotropium bromide(136310-93-5) inhalation therapy in 38 patients with chronic obstructive pulmonary disease

To investigate the changes of clinical symptoms and the improvement of pulmonary function in patients with chronic obstructive pulmonary disease (COPD) after treatment with tiotropium bromide(136310-93-5) inhalation. Methods: 76 patients with stable COPD were randomly divided into observation group and control group(38 cases). The control group was given salmeterol propionate fluticasone inhalation treatment, the observation group in the control group based on the addition of tiotropium bromide(136310-93-5) inhalants. Results: The scores of dyspnea and exercise tolerance were significantly better than those before treatment (P <0.05), and the improvement of the observation group was more significant (P <0.05). The indexes of lung function in the observation group were significantly better than those in the control group at 3, 6 and 12 months (P <0.05), and the control group was treated for 3 months. The index was significantly better than before treatment, 6 months and 12 months (P <0.05). Conclusion: Tiotropium inhalation can not only improve dyspnea and improve exercise tolerance, but also improve pulmonary function and improve the quality of life of patients with stable obstructive pulmonary disease.

To carry out the pharmacological study of tiotropium and ipratropium bromide in the clinical treatment of patients with chronic obstructive pulmonary disease(COPD), to provide the basis for clinical drug decision-making. METHODS: A retrospective study was conducted to screen patients with COPD in a hospital. The Markov model was used to simulate the patients receiving tiotropium bromide(136310-93-5) and ipratropium bromide. The results were compared with those of the relevant randomized controlled trials and published literature. Results: The results of the three-year tiotropium group and ipratropium bromide group were 3.90 and 3.87, respectively, and the tiotropium group was 5 792.55 yuan, which was 1 262.9 yuan less than that of the control group, Incremental cost - effect ratio of 119 977.67 yuan / QALY. CONCLUSIONS: During the treatment of COPD, the efficacy of the tiotropium group and the ipratropium bromide group was comparable in the 5-year period, but the cost of the tiotropium group was lower and the cost was more cost-effective.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved